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Reports of primary diffuse large B-cell lymphomas of the chest wall are extremely rare in the literature. We report
the case of a 62-year-old Chinese woman presenting with left-sided chest pain. A computed tomography scan
showed a solid, round mass in the left anterior chest wall, involving the second and third costal cartilages.
Complete resection and reconstruction of the chest wall was performed. The histological and immunohistochemical
features of the mass were used to diagnose a primary diffuse large B-cell lymphoma.
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Primary diffuse large B-cell lymphoma (DLBCL) of the
chest wall is an extremely rare disease. The disease most
often develops in the pleural cavity in patients with a
long-standing history of pyothorax, and it is therefore
thought to be pyothorax-associated [1-5]. The nonspe-
cific clinical and radiological presentation often makes
accurate diagnosis difficult; excision or incisional biop-
sies are needed for a definite pathologic diagnosis. Pa-
tients have a relatively good prognosis, especially when
the diagnosis is made at a local stage suitable for surgical
resection. We report the case of a patient with a rare
primary DLBCL of the chest wall and describe her treat-
ment course.
Case presentation
A 62-year-old Chinese woman presented to our depart-
ment complaining of intermittent left-sided chest pain
for the past six months. No other symptoms such as
fever, cough, dyspnea, or weight loss were present. Her
medical history showed five years of well-controlled
hypertension. She had no personal history of trauma or
surgery, and she had no family history of cancer. Her
physical examination revealed a palpable, immobile, rub-
bery, subcutaneous mass in the left anterior chest wall,
measuring approximately 7 cm × 7 cm. An evaluation* Correspondence: huntercj2004@yahoo.com; zhouqh135@163.com
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reproduction in any medium, provided the orwith a computed tomography (CT) scan revealed a solid,
round mass in the left anterior chest wall, involving the
second and third costal cartilages. Some bone destruc-
tion was noted and considered to be a sign of malig-
nancy (Figure 1). Her abdominal and brain CT scan
were negative for metastasis.
We decided on surgical intervention for both diagnosis
and treatment; a standard median sternotomy was per-
formed on 20 February 2012. The tumor was located in the
left anterior chest wall, involving the second and third cos-
tal cartilages, with the medial border of the tumor reaching
the sternum and costal cartilage junction. The tumor was
resected en-bloc with the surrounding tissues. A recon-
struction of the chest wall was performed using polyethyl-
ene terephthalate surgical mesh.
The gross tumor measured 75 mm× 70 mm× 15 mm,
with pleura covering the posterior surface. The cut surface
was soft and yellowish-gray in color, with visible areas of
bone tissue representing the resected ribs. A pathological
examination revealed a highly pleomorphic large-cell prolif-
eration. Immunohistochemistry was diffusely positive for
CD20, paired box protein 5 (PAX-5), and B-cell lymphoma
6 protein (Bcl-6) (Figure 2). The Ki-67 index was between
60 and 70%. The tumor cells were negative for a cluster of
differentiation 3 (CD3), CD10, CD117, CD43, CD68, mye-
loperoxidase (MPO), lysozyme, multiple myeloma onco-
gene 1 (MUM-1), and CD138. From these findings, we
diagnosed the tumor as DLBCL with an immunohistologi-
cal staining pattern consistent with germinal center B-cell
derivation.. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
Figure 1 Computed tomography scan showing a solid, round mass in the left anterior chest wall.
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chemotherapy was administered after surgery when she
was referred to the Department of Hematology. At
17 months after surgery, there is no evidence of local re-
currence or distal metastasis.
Discussion
Primary lymphoma of the chest wall is quite rare. In a
patient series described by Press et al., 4 of 250 patients
(1.6%) with lymphoma only had the disease in the chest
wall; this included a single patient with non-Hodgkin
lymphoma [6]. In another retrospective report, 7 of 157
patients with non-Hodgkin lymphoma initially presented
with a large chest-wall mass. In these few reports of pri-
mary lymphoma of the chest wall, DLBCL is the most
common subtype [7].
DLBCL is a group of large, lymphoid B-cell malignant
proliferations that is clinically, morphologically, and gen-
etically heterogenous. It constitutes about 30% of all
non-Hodgkin lymphomas and is the most common
histologic subtype [8]. Most reported DLBCLs of the
chest wall are pyothorax-associated lymphomas (PALs) -
tumors that develop in the pleural cavity of patients with
long-term pyothorax. This pyothorax, in turn, results
from artificial pneumothorax created for the treatment
of lung tuberculosis or tuberculous pleuritis. PAL is
strongly associated with the latency III form of the
Epstein-Barr virus (EBV) infection [1-5,9,10]. Cytokines
such as interleukin 6 (IL-6) and IL-10, produced at the
site of chronic inflammation, may induce a local im-
munosuppressive environment that plays an important
role in lymphomagenesis [11-13]. An elevated serum
neuron-specific enolase level in patients with chronic
pyothorax may be an indicator of PAL development [14].
Most PALs have an immunohistological staining patternconsistent with late germinal center and/or post germinal
center B-cell derivation [15-17].
Fujimoto et al. [18] reported the case of a patient with
EBV-associated DLBCL that developed in the chest wall
after a polyethylene terephthalate surgical mesh was im-
planted during surgery for a squamous cell lung carcin-
oma. In that case, the patient’s disease resembled a
typical PAL in many aspects such as the location, immu-
nostaining pattern, and the latent III form of EBV infec-
tion. The authors concluded that surgical implants can
be a cause of localized, long-standing inflammation,
which might enable EBV-transformed B-cells to escape
from host immune surveillance. This could then lead to
lymphomagenesis, as seen in PAL. Fouad et al. [19]
reported the case of another patient with DLBCL that
developed in the chest wall. The patient had a history of
blunt trauma with swelling and rib fracture, 41 years
prior. The immunophenotype was similar to PAL - a
non-germinal center phenotype. The authors proposed
that post-traumatic chronic inflammation lead to tumor
proliferation, with a similar mechanism to that seen in
PAL.
Our patient is unusual when compared to the previ-
ously reported instances of chest-wall DLBCL. She has
no history of pyothorax or chest-wall trauma that could
be a cause of chronic inflammation. Unlike typical PAL,
the immunohistological staining pattern in our patient
indicates a germinal center B-cell derivation.
The malignancy’s stage and histopathological diagnosis
have a major impact on its treatment and prognosis. Pa-
tients with lymphoma are usually treated with chemo-
therapy or local irradiation. It remains controversial
whether patients with lymphoma located only in the
chest wall should receive surgical resection. Hodgson
et al. [20] reported the outcomes in 324 patients with
Figure 2 Hematoxylin and eosin (H&E) staining showing a highly pleomorphic large-cell proliferation. Immunohistochemistry was
diffusely positive for CD20, paired box protein 5 (PAX-5), and B-cell lymphoma 6 protein (Bcl-6). The Ki-67 index was between 60 and 70%.
(Magnification shown at ×100 and ×400).
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with chemotherapy and local irradiation. They found
that patients with chest-wall invasion had poor local
control and survival. Romagurea et al. [21] reported that
surgical debulking is associated with improved survival
in stage I-II diffuse large-cell lymphoma.
In the few reported cases of DLBCL of the chest wall,
surgery provided a relatively satisfactory outcome. Luh
et al. [1] reported a patient with DLBCL developing from
a long-standing pyothorax of the left lower chest wall. In
that case, the patient remained free of local recurrence or
metastasis at nine months after surgical resection, without
further chemotherapy [5]. In Hsu et al.’s series [7], 3 of
the 4 patients with isolated chest wall lymphoma were
managed with surgical resection and adjuvant chemother-
apy. No tumor recurrence was recorded during the follow
up period, which had a maximum duration of 171 months.
Treatment after surgical resection is often based on acombination chemotherapy regimen. DLBCL is frequently
treated using CHOP (cyclophosphamide, doxorubicin,
vincristine, and prednisone); rituximab may improve the
response to CHOP treatment, as has been shown in sys-
temic DLBCL.
Our patient’s staging included an abdominal and brain
CT scan, which gave no indication of metastasis. She
underwent en-bloc resection of the tumor and chest wall
with adjuvant chemotherapy. She remains without evi-
dence of local recurrence or distal metastasis, at more
than one year after treatment. We conclude that surgery
followed by adjuvant chemotherapy can provide a satis-
factory outcome in patients with DLBCL isolated to the
chest wall.
Conclusions
When complete resection can be achieved, surgery should
be the treatment of choice in patients with localized
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http://www.wjso.com/content/12/1/104DLBCL. To the best of our knowledge, primary DLBCL of
the chest wall is extremely rare, with few cases reported in
the literature. Our patient is unusual, both in clinical pres-
entation and immunophenotype.
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